Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Commercial Services

Exclusive interview

Embedded service providers are future of the industry, says RPS

By Natalie Morrison+

21-Nov-2011

Loading...

Contract services providers which embed service personnel in pharma companies are becoming more prominent in the industry.

The firms recruit the researchers and specialists needed to run a project, before integrating them within businesses without the resources.

Last week, Outsourcing-Pharma reported the latest in a line of developments for the embedded services market with a four-facility expansion for Icon’s staffing and resources division DOCS .

And if industry insiders are to be believed this is just a taster of what is in store. For some, the business model has become an alternative to outsourcing to a CRO (contract research organisation) to reduce overheads.

Joseph Camero is executive recruiter for RPS, who provides employees as a service for pharmas and large biotech companies.

He spoke to Outsourcing-Pharma at this year’s AAPS conference in Washington about the future of embedded service providers in the industry and why there is a growing need for the provision.

“This is an alternative to using a CRO,” said Camero.

“Rather than outsourcing to other companies where they don’t really know the true experience or skills level of analysts working within those facilities, and at any given time these labs could be working on a multitude of different projects which could take precedence in the pecking order, we provide custom fit project teams of our employees.

“They work on assignments within our client companies.”

He added that staffing as a service could be a solution to the increasing number of facilities forced to close to reduce their overheads.

“The trend of the pharmaceutical industry is leaning towards outsourcing – large pharma companies are no longer doing that true clinical R&D (research and development). It is being outsourced.

“Some of these pharmaceutical companies have large R&D facilities that they either have to shut down or downsize to reduce the overheads and budgetary requirements.

“We can step in and covert employees to permanent RPS employees so they can still use their facilities and employees, and get their project to market on time.”

Related products

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Sue Mackay

Research nursing team manager, ResearchNurses.co

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

Kemwell and Boehringer set to finish biologics plant in India

Kemwell and Boehringer set to finish biologics plant in India

Christian Ahlmark

Director of corporate development , Kemwell

Key Industry Events

 

Access all events listing

Our events, Events from partners...